Compare Novartis AG (NVS) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Invesco S&P 500 Low Volatility ETF — how do they compare? Novartis AG trades at $142.74 (market cap $268.57B), while Invesco S&P 500 Low Volatility ETF trades at $71.97 (market cap $6.94B). The key difference: Novartis AG is far larger — about 38.7× Invesco S&P 500 Low Volatility ETF's market cap, and Novartis AG pays a 3.31% dividend while Invesco S&P 500 Low Volatility ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Invesco S&P 500 Low Volatility ETF for 123 Days on average.
| NVS | SPLV | |
|---|---|---|
Market Cap | $268.57B | $6.94B |
Volume | 1,532,573 | 1,663,703 |
Sector | Health | — |
52-Week High | $168.62 | $77.97 |
52-Week Low | $121.80 | $70.30 |
Typical Hold Time | 82 Days | 123 Days |
Enterprise Value | $309.89B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
SPLV trades at $71.22, down 0.71% with a bearish technical outlook. The ETF shows neutral oscillators but bearish moving averages, with key resistance at $72. Recent news highlights sector overweights in Utilities and Real Estate as headwinds, with the fund lagging the S&P 500's performance. Dividend payments of $0.14 are scheduled for July and September 2026.
Outlook remains cautious due to technical weakness and unappealing growth-adjusted valuation. Risks include concentrated sector exposure and macroeconomic pressures. The fund's low-volatility strategy may appeal during market uncertainty, but current technicals suggest limited near-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
